{
    "organizations": [],
    "uuid": "d1ebd6b30d964c8470f4e92db0960f8537ca4a96",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-amag-pharmaceuticals-submits-nda-t/brief-amag-pharmaceuticals-submits-nda-to-fda-for-bremelanotide-idUSASC09TL9",
    "ord_in_thread": 0,
    "title": "BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Amag Pharmaceuticals Inc:\n* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-26T20:21:00.000+03:00",
    "crawled": "2018-03-27T11:48:09.036+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "amag",
        "pharmaceutical",
        "inc",
        "amag",
        "pharmaceutical",
        "submits",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "bremelanotide",
        "treatment",
        "hypoactive",
        "sexual",
        "desire",
        "disorder",
        "hsdd",
        "premenopausal",
        "woman",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}